Condition: HER2-positive Advanced Gastric Cancer · HER2-positive Gastroesophageal Junction Adenocarcinoma · Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.
This description comes directly from the study's public registry record.
Contact for Clinical Trial Information · 908-992-6400 · CTRinfo@dsi.com
Always discuss trial participation with your own doctor first.
| KABEG Klinikum Klagenfurt am Wörthersee - Landeskrankenanstalten LKH | Klagenfurt, Austria | Withdrawn |
| Ordensklinikum Linz GmbH Barmherzige Schwestern | Linz, Austria | Active Not Recruiting |
| Universitätsklinikum St. Pölten - Lilienfeld | Sankt Pölten, Austria | Withdrawn |
| Medizinische Universität Wien | Vienna, Austria | Active Not Recruiting |
| St. Josef Krankenhaus GmbH Ein Unternehmen der Vinzenz Gruppe | Vienna, Austria | Withdrawn |
| Klinik Ottakring, Wilhelminenspital der Stadt Wien | Vienna, Austria | Withdrawn |
| Kepler Universitätsklinikum | Wels, Austria | Active Not Recruiting |
| Landesklinikum Wiener Neustadt | Wiener Neustadt, Austria | Active Not Recruiting |
| Krankenhaus St. Vinzenz in Zams | Zams, Austria | Active Not Recruiting |
| OLV Hospital Aalst | Aalst, Belgium | Active Not Recruiting |
| Imelda vzw | Bonheiden, Belgium | Withdrawn |
| HUB institut Jules Bordet | Brussels, Belgium | Withdrawn |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05993234